Anti-HBs responses to vaccination with a human hepatitis B vaccine made by recombinant DNA technology in yeast.
Anti-HBs responses to vaccination with a human hepatitis B vaccine made by recombinant DNA technology in yeast.
复制标题
接种通过酵母重组 DNA 技术制成的人类乙型肝炎疫苗后可产生抗 HBs 反应。
DOI：
10.1093/infdis/153.1.156
复制
发表时间：
1986
期刊：
影响因子：
--
通讯作者：
Pepe,PE
中科院分区：
文献类型：
--
作者：
Hollinger,FB;Troisi,CL;Pepe,PE
In the United States, the currently licensed vaccine against hepatitis B virus (HEPTAVAX-B (R); Merck Sharp & Dohme, West Point, Pa) consists of hepatitis B surface antigen (HBsAg) that is purified from the plasma of chronically infected humans. Antibodies to the group a determinant of this complex antigen effectively neutralize the various subtypes of hepatitis B virus (HBV), as shown in a number of controlled clinical trials [1-3]. Despite overwhelming evidence that documents the efficacy of this vaccine, widespread acceptance by those who are at greatest risk of contracting hepatitis B has been less than expected be-cause of a number of unrelated factors. The plasma-derived vaccine is expensive to prepare. A number of physical and chemical inactivation steps are used in purification, and extensive safety testings are mandated by the Food and Drug Administration in laboratory animals, cell cultures, and chimpanzees before the product can be marketed. In addition, there are of necessity batch-to-batch variations in human source material. These problems would have been surmountable in the marketing of this vaccine were it not for two recent events that made potential vaccine candidates overly cautious about accepting this new product: the increased incidence of Guillain-Barre syndrome that followed administration of the swine influenza vaccine in 1976 and the emergence of AIDS in the homosexual population. The latter problem was particularly relevant because HEPTAVAX-B is a plasma-derived product obtained from HBsAg-positive individuals, some of whom are in high-risk groups for AIDS. This raised the question whether AIDS might be transmitted to recipients of this vaccine. Unfortunately, despite numerous studies [4, 5] that eventually have refuted this hypothesis (on the basis of the susceptibility of retroviruses to inactivation by the phys-ical and chemical steps used in producing the vaccine and by the lack of cases of AIDs or antibody seroconversions to human T lymphotropic virus type III observed among
